Cargando…
Docking, Binding Free Energy Calculations and In Vitro Characterization of Pyrazine Linked 2-Aminobenzamides as Novel Class I Histone Deacetylase (HDAC) Inhibitors
Class I histone deacetylases, HDAC1, HDAC2, and HDAC3, represent potential targets for cancer treatment. However, the development of isoform-selective drugs for these enzymes remains challenging due to their high sequence and structural similarity. In the current study, we applied a computational ap...
Autores principales: | Bülbül, Emre F., Melesina, Jelena, Ibrahim, Hany S., Abdelsalam, Mohamed, Vecchio, Anita, Robaa, Dina, Zessin, Matthes, Schutkowski, Mike, Sippl, Wolfgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032825/ https://www.ncbi.nlm.nih.gov/pubmed/35458724 http://dx.doi.org/10.3390/molecules27082526 |
Ejemplares similares
-
Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity
por: Ibrahim, Hany S., et al.
Publicado: (2021) -
Application of Ligand- and Structure-Based Prediction Models for the Design of Alkylhydrazide-Based HDAC3 Inhibitors as Novel Anti-Cancer Compounds
por: Bülbül, Emre F., et al.
Publicado: (2023) -
Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
por: Ghazy, Ehab, et al.
Publicado: (2022) -
Continuous Activity Assay for HDAC11 Enabling Reevaluation
of HDAC Inhibitors
por: Kutil, Zsófia, et al.
Publicado: (2019) -
A Novel Class of Schistosoma mansoni Histone Deacetylase 8 (HDAC8) Inhibitors Identified by Structure-Based Virtual Screening and In Vitro Testing
por: Simoben, Conrad V., et al.
Publicado: (2018)